BeOne Medicines
ONC
#654
Rank
A$54.69 B
Marketcap
A$494.28
Share price
-4.54%
Change (1 day)
20.91%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeOne Medicines (ONC)

Earnings in 2025 (TTM): A$0.27 Billion

According to BeOne Medicines's latest financial reports the company's current earnings are A$4.97 Billion. In 2024 the company made an earning of -A$0.8 Billion, an increase over its 2023 earnings that were of -A$1.7 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeOne Medicines from 2015 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) A$0.27 B-133.92%
2024 -A$0.8 Billion-52.95%
2023 -A$1.7 Billion-32.52%
2022 -A$2.52 Billion24.39%
2021 -A$2.02 Billion-13.21%
2020 -A$2.33 Billion72.69%
2019 -A$1.35 Billion36.01%
2018 -A$1 Billion616.83%
2017 -A$0.14 Billion-15.24%
2016 -A$0.17 Billion107.91%
2015 -A$78.41 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
OPKO Health
OPK
-A$0.23 Billion-187.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-A$25.48 Million-109.94%๐Ÿ‡บ๐Ÿ‡ธ USA